Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Paracetamol may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
FOR Paracetamol Oral Solution contains paracetamol which is a pain-killer and also reduces a fever (high body temperature). This medicine is a higher strength Paracetamol Oral Solution. It is used for mild to moderate pain when you cannot take other paracetamol formulations such as lower strength liquid paracetamol, effervescent tablets or tablets.
E PARACETAMOL ORAL SOLUTION Do not take Paracetamol Oral Solution:
During treatment with Paracetamol Oral Solution, tell your doctor straight away if:
Driving and using machines There are no known effects on the ability to drive and use machines. Paracetamol Oral Solution contains:
the oral syringe: 1. Shake the bottle well, making sure the cap is firmly on the bottle. 2. Remove the cap. Note: Keep the cap nearby to close the bottle after each use. 3. Push the plastic adapter into the neck of the bottle. 4. Take the syringe and check the plunger is fully down. 5. Keep the bottle upright and insert the oral syringe firmly into the plastic adapter.
6. Turn the whole bottle with the syringe upside down. 7. Slowly pull the plunger down fully so that the syringe fills with medicine. Push the plunger back up, to completely expel any large air bubble that may be trapped inside the oral syringe. 8. Then pull the plunger slowly back to the volume you need for your dose. 9. Turn the whole bottle with the syringe the right way up and take the syringe out of the bottle. 10. The dose of medicine can now be swallowed directly from the oral syringe. Please ensure that you are sitting upright and the plunger must be pushed slowly to allow you to swallow the dose. After administration remove the adaptor from the bottle, wash it and allow to dry till you use it the next time. 11. Replace the child proof cap after use.
12. Cleaning: After use, wipe the tip of the syringe with a dry, clean tissue. Do not give this medicine with any other paracetamol containing product. Do not exceed the stated dose. The recommended dose is Adults and young persons 16 years and over 500mg (5ml) to 1000mg (10ml) up to three to four times a day, as required. Maximum daily intake should not exceed 4g (40ml). How often to take
Like all medicines, this medicine can cause side effects, although not everybody gets them. Some side effects can be serious and you should tell your doctor immediately if you notice the following
The following side effects have also been reported: Very rare (may affect up to 1 in 10,000 people)
PARACETAMOL ORAL SOLUTION
What Paracetamol Oral Solution contains
Kleva Pharmaceuticals SA 189 Parnithos Ave 13675 – Acharnai, Greece This leaflet was last revised in January 2025.
Paracetamol 500mg/5ml Oral Solution comes as oral solution containing 500mg / 5ml. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Paracetamol 500mg/5ml Oral Solution is paracetamol.
Medicines with the same active substance, strength and form include: Paracetamol Adult 500mg/5ml Oral Suspension. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Paracetamol 500mg/5ml Oral Solution, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Paracetamol solution is indicated in the management of pain and fever associated with such conditions as the common cold, influenza and headache.
For patients who are unable to tolerate solid dose formulations or lower strength preparations of paracetamol containing products.
Posology:
Recommended Doses and Dosage Schedules
Adults and young persons 16 years and over:
The Optimal dosage range is 500mg (5ml) to 1000mg (10ml) up to three to four times a day, as required, to a maximum of 4 g paracetamol/ day (40 ml paracetamol oral solution).
The dose should not be repeated more frequently than every four hours, and not more than four doses should be taken in any 24 hour period.
Elderly:
In older people, the rate and extent of paracetamol absorption is normal but plasma half-life is longer and paracetamol clearance is lower than in young adults.
Paediatric Population
Do not use this medicine in children and adolescents under 16 years.
Method of administration
For oral administration only.
It is important to shake the bottle for at least 10 seconds well before use.
Hypersensitivity to paracetamol or any of the excipients listed in section 6.1.
Patients with severe hepatic dysfunction.
Do not use this medicine in children and adolescents under 16 years.
Care is advised in the administration of paracetamol to patients with severe renal or severe hepatic impairment. The hazards of overdose are greater in those with (non- cirrhotic) alcoholic liver disease.
Do not take with any other paracetamol-containing products.
Cases of high anion gap metabolic acidosis (HAGMA) due to pyroglutamic acidosis have been reported in patients with severe illness such as severe renal impairment andsepsis or in patients with malnutrition or other sources of gluthione deficiency (e.g. chronic alcoholism) who were treated with paracetamol at therapeutic dose for a prolonged period or a combination of paracetamol and flucloxacillin. If HAGMA due to pyroglutamic acidosis is suspected, prompt discontinuation of paracetamol and close monitoring is recommended. The measurement of urinary 5-oxoproline may be useful to identify pyroglutamic acidosis as underlying cause of HAGMA in patients with multiple risk factors.
Talk to a doctor at once if you take too much of this medicine, even if you feel well. This is because too much paracetamol can cause delayed, serious liver damage.
Do not exceed the recommended dose.
Keep out of the sight and reach of children.
Excipient warnings:
This product contains the following excipients:
Parahydroxybenzoates: these may cause allergic reactions (possibly delayed).
Propylene glycol: this medicine contains 1530 mg propylene glycol in each 5ml. Therefore, this medicine should be used with caution in pregnancy, breastfeeding, liver or kidney disease.
Glycerol: may cause headache, stomach upset and diarrhoea.
This medicine contains 4.25mg/5ml (0.18 mmol) of sodium which is essentially 'sodium free'.
The hepatotoxicity of Paracetamol, particularly after overdosage, may be increased by drugs which induce liver microsomal enzymes such as barbiturates, tricyclic antidepressants and alcohol.
Alcohol can increase the hepatotoxicity of paracetamol overdosage.
The speed of absorption of paracetamol may be increased by metoclopramide or domperidone and absorption reduced by cholestyramine.
The anticoagulant effect of warfarin and other coumarins may be enhanced by prolonged regular use of paracetamol with increased risk of bleeding; occasional doses have no significant effect.
Antivirals: Regular use of Paracetamol possibly reduces metabolism of Zidovudine (increased risk of neutropenia).
Caution should be taken when paracetamol is used concomitantly with flucloxacillin as concurrent intake has been associated with high anion gap metabolic acidosis due to pyroglutamic acidosis, especially in patients with risk factors. (See section 4.4).
Pregnancy:
Epidemiological studies in human pregnancy have shown no ill effects due to paracetamol used in the recommended dosage, but patients should follow the advice of their doctor regarding its use.
A large amount of data on pregnant women indicate neither malformative, nor feto/neonatal toxicity. Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results. If clinically needed, paracetamol can be used during pregnancy however it should be used at the lowest effective dose for the shortest possible time and at the lowest possible frequency.
Breast-feeding:
Paracetamol is excreted in breast milk but not in clinically significant amount.
Available published data do not contraindicate breast feeding.
Fertility:
There are no data on the effects of this medicine on human fertility.
None known
The information below lists reported adverse reactions, ranked using the following frequency classification:
Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).
System Organ Class
Frequency
Adverse Events
Blood and lymphatic system disorders
Not known
Blood dyscrasia including thrombocytopenia and agranulocytosis1
Immune system disorders
Not known
Anaphylactic shock, angioedema, anaphylactic reaction, urticaria, hypersensitivity, rash
Metabolism and nutrition disorders
Not known
High anion gap metabolic acidosis4
Gastrointestinal disorders
Not known
Acute Pancreatitis2
Skin and subcutaneous disorders
Very Rare
Serious skin reactions
Renal and urinary disorders
Uncommon
Nephropathy toxic3
1But these were not necessarily causally related to Paracetamol.
2Paracetamol has been widely used and reports of adverse reactions are rare, and are generally associated with overdosage.
3Nephrotoxic effects are uncommon and have not been reported in association with therapeutic doses, except after prolonged administration.
4 Cases of high anion gap metabolic acidosis due to pyroglutamic acidosis have been observed in patients with risk factors using paracetamol (see section 4.4).
Pyroglutamic acidosis may occur as a consequence of low glutathione levels in these patients.
Reporting of suspected adverse reactions:
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Liver damage is possible in adults who have taken 10g or more of paracetamol. Ingestion of 5g or more of paracetamol may lead to liver damage if the patient has the risk factors.
Risk Factors:
If the patient
a) Is on long term treatment with carbamazepine, phenobarbitone, phenytoin, primidone, rifampicin, St John's Wort or other drugs that induce liver enzymes.
OR
b) Regularly consumes ethanol in excess of recommended amounts.
OR
c) Is likely to be glutathione deplete e.g. eating disorders, cystic fibrosis, HIV infection, starvation, cachexia.
Symptoms:
Symptoms of paracetamol overdosage in the first 24 hours are pallor, nausea, vomiting, anorexia and abdominal pain. Liver damage may become apparent 12 to 48 hours after ingestion. Abnormalities of glucose metabolism and metabolic acidosis may occur. Hyperglycaemia has been reported. In severe poisoning, hepatic failure may progress to encephalopathy, haemorrhage, hypoglycaemia, cerebral oedema and death. Acute renal failure with acute tubular necrosis, strongly suggested by loin pain, haematuria and proteinuria may develop even in the absence of severe liver damage. Cardiac arrhythmias and pancreatitis have been reported.
Management
Immediate treatment is essential in the management of paracetamol overdose. Despite a lack of significant early symptoms, patients should be referred to hospital urgently for immediate medical attention. Symptoms may be limited to nausea or vomiting and may not reflect the severity of overdose or the risk of organ damage. Management should be in accordance with established treatment guidelines, see BNF overdose section.
Treatment with activated charcoal should be considered if the overdose has been taken within 1 hour. Plasma paracetamol concentration should be measured at 4 hours or later after ingestion (earlier concentrations are unreliable). Treatment with N-acetylcysteine may be used up to 24 hours after ingestion of paracetamol; however, the maximum protective effect is obtained up to 8 hours post-ingestion. The effectiveness of the antidote however declines sharply after this time. If required the patient should be given intravenous N-acetylcysteine, in line with the established dosage schedule. If vomiting is not a problem, oral methionine may be a suitable alternative for remote areas, outside hospital. Management of patients who represent with serious hepatic dysfunction beyond 24h ingestion should be discussed with the NPIS or a liver unit.
Ask anything about Paracetamol 500mg/5ml Oral Solution. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.